Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis.
There is an urgent need for novel therapeutics to treat Mycobacterium tuberculosis infections. Genetic strategies for validating novel targets are available, yet their time-consuming nature limits their utility. Here, using MmpL3 as a model target, we report on the application of mycobacterial CRISPR interference for the rapid validation of target essentiality and compound mode of action. This strategy has the potential to rapidly accelerate tuberculosis drug discovery.
['McNeil|Matthew B|MB|', 'Cook|Gregory M|GM|']
D000995:Antitubercular Agents D001426:Bacterial Proteins D064112:Clustered Regularly Interspaced Short Palindromic Repeats D016503:Drug Delivery Systems D006801:Humans D026901:Membrane Transport Proteins D009169:Mycobacterium tuberculosis D014376:Tuberculosis
CRISPRi molecular genetics mycobacteria